Daniel Keizman, Moshe Frenkel, Avivit Peer, Igal Kushnir, Eli Rosenbaum, David Sarid, Ilan Leibovitch, Roy Mano, Ofer Yossepowitch, David Margel, Ido Wolf, Ravit Geva, Hadas Dresler, Keren Rouvinov, Noa Rapoport, Isaac Eliaz
Optimal therapy of biochemically relapsed prostate cancer (BRPC) after local treatment is elusive. An established modified citrus pectin (PectaSol® , P-MCP), a dietary polysaccharide, is an established antagonist of galectin-3, a carbohydrate-binding protein involved in cancer pathogenesis. Based on PSA dynamics, we report on the safety and the primary outcome analysis of a prospective phase II study of P-MCP in non-metastatic BRPC based. Sixty patients were enrolled, and one patient withdrew after a month...
November 28, 2021: Nutrients